{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:04Z","timestamp":1787955964328,"version":"build-2784847793"},"reference-count":46,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Atopic dermatitis (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>) is a common inflammatory skin disease in both adults and children. Whilst topical calcineurin inhibitors (<jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content>s), tacrolimus ointment and pimecrolimus cream, have proven efficacy for the treatment of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>, it is important to involve experts to obtain their opinion on its optimal treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Using a modified Delphi approach, this project aimed to generate consensus amongst experts on the use of <jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content>s in the treatment of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>, with a focus on the differentiation between tacrolimus and pimecrolimus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six expert dermatologists from different European countries participated in this project based on their experience with <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> and its treatment, which was evaluated by literature analysis and expert opinion. Consensus amongst the experts was generated using a modified Delphi approach, consisting of three distinct phases, during which a web meeting (June 2017), two online rounds of blinded Delphi voting (July\u2013September 2017) and a face\u2010to\u2010face meeting (November 2017) were conducted. The consensus statements concerned two main topics: (i) Background of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>; and (ii) <jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content>s in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>. Hot topics in the treatment of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> not supported by meta\u2010analysis, clinical trials or large observational studies were also discussed based on clinical experience.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 25 consensus statements were defined and validated: eight statements on the general background of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> and 17 statements on the use of <jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content>s in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>, including their mechanism of action and therapeutic indications in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>, efficacy in adult and paediatric <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients, pharmacokinetics, incidence of adverse events and safety concerns. Hot topics on the use of <jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content>s for the treatment of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> included cream vs. ointment, dosages, <jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content>s contact allergy, burning sensation management, superinfection and vaccination concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Topical calcineurin inhibitors are a suitable therapy for <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>, and selection of the specific <jats:styled-content style=\"fixed-case\">TCI<\/jats:styled-content> should be based on factors which differentiate tacrolimus from pimecrolimus.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15272","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:29:06Z","timestamp":1538796546000},"page":"2074-2082","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Position statement: topical calcineurin inhibitors in atopic dermatitis"],"prefix":"10.1111","volume":"32","author":[{"given":"A.","family":"Remitz","sequence":"first","affiliation":[{"name":"Department of Skin and Allergic Diseases Helsinki University Central Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"De Pit\u00e0","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Cristo Re Hospital Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mota","sequence":"additional","affiliation":[{"name":"Department of Dermatology Faculty of Medicine University of Porto i3S Research Institute Porto Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Serra\u2010Baldrich","sequence":"additional","affiliation":[{"name":"Department of Dermatology Sant Pau Hospital Autonomous University Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vakirlis","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology Aristotle University Medical School Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kapp","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy Hannover Medical School Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja17.00463"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.03.010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2017.009"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0170-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.02.007"},{"key":"e_1_2_8_7_1","first-page":"CD009864","article-title":"Topical tacrolimus for atopic dermatitis","volume":"7","author":"Cury Martins J","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381948"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2437"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03415.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04635.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06017.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00323.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12778"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2013.35619"},{"key":"e_1_2_8_17_1","unstructured":"Tacrolimus (Protopic 0.1% and 0.03% ointment) summary of product characteristics (SmPC). URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000374\/WC500046824.pdf(last accessed: 17 March 2018)."},{"key":"e_1_2_8_18_1","unstructured":"Pimecrolimus 1% summary of product characteristics (SmPC). URLhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Elidel_31\/WC500012315.pdf(last accessed: 17 March 2018)."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203060-00002"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38376.439653.D3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08813.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13599"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01683.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.023"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.12.038"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701287332"},{"key":"e_1_2_8_27_1","first-page":"185","article-title":"Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis","volume":"6","author":"Krueger GG","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0748"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.02.028"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0013-9"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0020-1"},{"key":"e_1_2_8_32_1","first-page":"692","article-title":"How to improve adherence to treatment in patients with mild\u2010to\u2010moderate psoriasis? An expert opinion","volume":"153","author":"Piaserico S","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.711756"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.061"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2006.00948.x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2007.06028"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2010.01764.x"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.013"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2005.00693.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484407"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2699"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09757.x"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.5070\/D31S72G865"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.275"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.094276"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.08.046"},{"key":"e_1_2_8_47_1","first-page":"372","article-title":"Cost\u2010effectiveness of tacrolimus ointment versus pimecrolimus cream in adults with atopic dermatitis","volume":"9","author":"Taneja C","year":"2010","journal-title":"J Drugs Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:17:31Z","timestamp":1694751451000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/jdv.15272"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15272","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"2018-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}